Paper Details

  1. Home
  2. Paper Details

BCL-2 inhibitor synergizes with PI3Kδ inhibitor and overcomes FLT3 inhibitor resistance in acute myeloid leukaemia.

Author: HeYe, JiangHua-Liang, LingLi-Jun, WangYa-Fang, WenJie, XieCheng-Ying, YaoMing-Yue, ZhaoYu, ZhengMing-Yue

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Combining venetoclax, a BCL-2 inhibitor, with idelalisib, a PI3Kδ inhibitor, showed synergistic antitumor effects in acute myeloid leukemia (AML). This combination led to increased apoptosis and decreased MCL-1 expression, a key regulator of apoptosis, in AML cell lines. The combination therapy was particularly effective in a quizartinib-resistant AML model, suggesting its potential as a treatment option for patients with FLT3 mutations.
Paper Details　
Original Abstract of the Article :
Inhibitors targeting the antiapoptotic molecule BCL-2 have therapeutic potential for the treatment of acute myeloid leukaemia (AML); however, BCL-2 inhibitors such as venetoclax exhibit limited monotherapy efficacy in relapsed or refractory human AML. PI3Kδ/AKT signalling has been shown to be c...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442011/

データ提供：米国国立医学図書館（NLM）

Combating Acute Myeloid Leukemia: A Synergistic Approach

The fight against acute myeloid leukemia (AML) is like traversing a vast desert, seeking new ways to overcome this formidable disease. This research explores a promising synergistic approach, combining BCL-2 and PI3Kδ inhibitors. The authors demonstrate the potential of this combination to overcome the limitations of monotherapy with BCL-2 inhibitors and target the crucial PI3Kδ/AKT signaling pathway, ultimately enhancing antitumor effects.

A Dual-Pronged Attack: Synergistic Inhibition of BCL-2 and PI3Kδ

The study unveils the synergistic potential of combining BCL-2 and PI3Kδ inhibitors. The authors demonstrate that this combined approach significantly enhances antiproliferative effects, induces apoptosis, and even overcomes FLT3 inhibitor resistance in AML cells, suggesting a promising strategy for treating this aggressive disease.

A Beacon of Hope: Exploring New Avenues for AML Treatment

This research offers a ray of hope in the battle against AML. The synergistic approach of combining BCL-2 and PI3Kδ inhibitors presents a promising avenue for improving treatment outcomes and potentially extending the lives of patients with this challenging disease.

Dr.Camel's Conclusion

This research highlights the power of synergistic approaches in cancer treatment. By combining multiple targeted therapies, we can potentially overcome the limitations of individual drugs and achieve more effective outcomes for patients battling AML.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-09-20
Further Info :

Pubmed ID

36119822

DOI: Digital Object Identifier

PMC9442011

Related Literature

Article Analysis
・Effects of idelalisib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.